Formal Japanese approval for Erbitux
This article was originally published in Scrip
Executive Summary
ImClone Systems/Merck KGaA's EGFR-targeting antibody Erbitux (cetuximab) has received formal final approval from Japan's ministry of health, labour and welfare, for the treatment of inoperable, advanced or recurrent metastatic colorectal cancer.